GeneOnline & Select Biosciences‘s Diagnostics Summit Asia 2018 brings together researchers from across Asia/Pacific, US and Europe to focus on the emerging topics, themes, technologies and application areas in the various diagnostics arenas.
Topics addressed focus on point-of-care diagnostics, rapid and low-cost diagnostics for deployment worldwide, liquid biopsies for cancer and the development of immunoassays for various analyte classes of relevance in diagnostics.
In addition to scientific invited presentations, technology spotlight presentations from companies, a poster session will highlight late-breaking technologies and exhibitors will focus on products and services in this fast-evolving field.
此次大會特別邀請來自知名大廠 Roche、日本國立癌症研究中心、 美國洛杉磯加州大學（UCLA） 、荷蘭烏特勒支大學附設醫院等重量級專家學者，共同探討定點照護診斷(point-of-care diagnostic)、癌症液態生物檢體技術(liquid biopsies for cancer)、以及免疫分析(immunoassays)技術等的最新發展與全球趨勢
Lai-Kwan Chau, Professor, National Chung Cheng University
Ting-Shou Chen, Division Director, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute (ITRI)
Chris Wetzel, Director of Sales and Marketing, MMI Microscope-based Single Cell Isolation
Shi-Da Zhu, VP of Precision Medicine, BGI-Research
Confirmed Agenda (more TBA)
Monday, 5 November 2018
08:00 Conference Registration, Materials Pick-Up, Morning Coffee, Tea and Breakfast Pastries
Session Title: Emerging Themes in Diagnostics, circa 2018
Exosome Diagnosis Presents a Novel Platform for Liquid Biopsy
Takahiro Ochiya, Chief, National Cancer Center Research Institute Japan, Japan
Exosomes are 50-150 nm size in diameter extracellular vesicles (EVs) secreted by multiple living cells into the extracellular space. They contain tissue or cell-specific bioactive materials, including DNAs, mRNAs, ncRNAs, proteins, lipids, metabolites, etc. with their specific surface markers, such as, CD9, CD63, CD81, Alix, etc. Exosomes have been considered as information carriers in cell communication between cancer cells and non-cancer cells, which affect gene expressions and cellular signalling pathways of recipient cells by delivering their contents. Exosomes are promising tools for improving cancer care, but conversely may also contribute to tumor progression. Here, we highlight recently discovered roles of exosomes in modulating cancer microenvironment. We also discuss how exosomes could be exploited as biomarkers for a novel platform of liquid biopsy and delivery vehicles in cancer therapy.
Diagnostic Potential of Plasma Vesicles for Ischemic Heart Disease
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands
Cardiovascular Disease (CVD) is with the cardiovascular events of Ischemic Heart Disease and Stroke, the number 1 and 2 cause of death in the world and expect to increase especially in Asia. Ischemic heart disease (IHD) comprises 3 entities: stable coronary artery disease (SCAD), unstable angina (UA) and myocardial infarction (MI). Because IHD is associated with an increased risk of adverse clinical events such as heart failure and death, early recognition of IHD is of utmost importance. However, to diagnosis IHD is challenging, as many patients present with atypical symptoms. It is known that women have a different symptom sensation than men. Troponins are the main diagnostic tool for detection of MI. Blood biomarkers for SCAD (typically causing stable angina) and UA, however, are not available. These diagnoses frequently require hospital visits/admissions for time-consuming and costly (non)invasive tests. We use a protein signature measured in 3 different subsets of plasma extracellular vesicle as an accurate source for early diagnosis of SCAD and UA. Diagnosis of ischemic heart disease as well as normalization and characterization of extracellular vesicles in plasma subfractions will be discussed.
10:30 Morning Coffee Break and Networking
Early Assessment of Treatment Response in Solid Tumors via Quantitating Circulating Tumor DNA
Max Ma, Director, Medical Affairs, Roche Sequencing Solutions, Inc., United States of America
Thanks to the advancement of modern medicine, multiple therapeutic options often exist for the treatment of various cancers. Lessons learned from managing blood cancers under therapy have taught us the importance of early response. Longitudinal monitoring of circulating tumor DNA (ctDNA) is an emerging method for disease management in solid tumors. We employed a 197-gene NGS assay, the AVENIO ctDNA Surveillance Kit, which allowed us to perform longitudinal ctDNA analysis and measure changes in ctDNA levels in plasma. Specifically, we evaluated the association between change in ctDNA levels within first two cycles of treatment and survival data from a cohort of 106 advanced lung adenocarcinoma subjects treated with first-line chemo or chemoradiation therapies. Our data show that a decrease in post-treatment ctDNA level measured by the Surveillance Kit was associated with better outcome (both PFS and OS) in advanced lung adenocarcinoma. Thus, an early assessment of treatment effect can be measured using ctDNA in plasma within 1 or 2 treatment cycles.
12:00 Networking Lunch
NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells
Hsian-Rong Tseng, Professor, Crump Institute for Molecular Imaging, California NanoSystems Institute, University of California-Los Angeles, United States of America
Circulating tumor cells (CTCs) are cancer cells shredded from either a primary tumor or a metastatic site and circulate in the blood as the potential cellular origin of metastasis. By detecting and analyzing CTCs, we will be able to noninvasively monitor disease progression in individual cancer patients and obtain insightful information for assessing disease status, thus realizing the concept of “tumor liquid biopsy”. Over the past decade, our research team at UCLA pioneered a unique concept of “NanoVelcro” cell-affinity substrates, in which CTC capture agent-coated nanostructured substrates were utilized to immobilize CTCs with remarkable efficiency. Five generations of NanoVelcro CTC assays have been developed over the past decade for a variety of clinical utilities, including CTC enumeration for prognosis and staging, single-CTC mutational analysis for tracking tumor origin, and CTC-based molecular analysis for treatment monitoring. In this presentation, I will summarize the development of the new generations of NanoVelcro CTC assays and the clinical applications of these new diagnostic devices.
Integrating Aptamer Technology with Paper-Based Point-of-Care Devices for Biomedical Monitoring
John Brennan, Professor and Director, Biointerfaces Institute, McMaster University, Canada
DNA aptamers and DNA enzymes (denoted as functional nucleic acids or FNA) are an emerging platform for development of point-of-care (POC) diagnostic devices. In this presentation, I will first focus on the development of new aptamers and DNA enzymes for a range of key biomarkers and their integration into colorimetric and fluorimetric assays for a variety of targets, mainly in the area of infectious disease. Methods to couple target binding to FNAs to produce a DNA strand as an output, and to then use the output DNA to initiate isothermal amplification (ITA), will then be described. Finally, the printing of specific “modules” for recognition (FNA), amplification (via ITA) and detection onto paper devices will be described as a way to generate a range of new POC devices that allow facile detection of a range of clinical analytes. Examples will be provided to demonstrate multi-step reactions on paper for ultra-sensitive detection of E. coli, C. difficile, MRSA and H. pylori.
15:30 Afternoon Coffee Break
In the recent past, we reported the nanotube-CTC-chip for rapid classification of biomarkers using electrical signals and cell capture from droplets with 55-100% yield. In this talk, we will outline the further development of the nanotube-CTC-chip for highly efficient capture of CTCs with very high quality. Advantages of the nanotube-CTC-chip include both positive and negative selection strategy on the same chip resulting in potential to capture invasive CTC phenotypes with diverse population of cells. The nanotube-CTC-chip also enables culturing of cancer cells directly on the device for further analysis. Potentially one can achieve capture of CTCs based on multiple biomarkers, negative selection by depleting leukocytes, and density gradient based selection of nucleated cells, thereby avoiding loss of CTCs due to variation in size and biomarker composition in a single blood test.
A Rapid and Mobile Fiber Optic Nanoplasmonic Biosensor
Lai-Kwan Chau, Professor, National Chung Cheng University, Taiwan
A rapid and mobile biosensing platform for low-cost point-of-care testing based on fiber optic nanoplasmonics, which takes advantage of the multiple total internal reflections in an optical fiber to offer superior detection limits.
17:30 Networking Reception with Beer and Wine
18:30 Close of Day 1 of the Conference.
Call for Papers
If you would like to be considered for an oral presentation at this meeting, Submit an abstract for review now!
Oral Presentation Submission Deadline: 30 April 2018
Call for Posters
You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!
Poster Submission Deadline: 31 October 2018
BOOK YOUR SEAT NOW!
More Detail Coming Up Soon!
For More Information Please Contact GeneOnline:
[email protected] / +886-2-2514-0360